secwatch.observer — SEC 8-K summary
======================================

Issuer:     SUPERNUS PHARMACEUTICALS, INC. (SUPN)
CIK:        0001356576
Form:       8-K
Filed at:   2026-02-24T23:59:59+00:00
Accession:  0001356576-26-000004
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Supernus Q4 revenue $211.6M (+21% YoY), FY revenue $719M (+9%); FY26 guidance $840-870M
--------------------------------------------------------------------------------

- Record Q4 total revenue $211.6M (+21% YoY); full year $719.0M (+9% YoY).
- Growth products (Qelbree, GOCOVRI, ZURZUVAE, ONAPGO) combined revenue $161.3M in Q4 (+45% YoY).
- ONAPGO net sales $8.9M since launch; new patient initiation resumed Q1 2026; second supplier expected 2027.
- Cash and marketable securities $308.7M at Dec 31, 2025.
- FY 2026 guidance: revenue $840-870M, operating earnings $0-30M, adjusted operating earnings $140-170M.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1356576/000135657626000004/0001356576-26-000004-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1356576/000135657626000004/supn-20260224.htm
  HTML page:      https://secwatch.observer/filing/0001356576-26-000004

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer